## JOURNAL OF CLINICAL ONCOLOGY

## ORIGINAL REPORT

# Psychological Distress in Adult Survivors of Childhood Cancer: The Swiss Childhood Cancer Survivor Study

Gisela Michel, Cornelia E. Rebholz, Nicolas X. von der Weid, Eva Bergstraesser, and Claudia E. Kuehni

From the Swiss Childhood Cancer Registry, Institute of Social and Preventive Medicine, University of Bern, Bern; Paediatric Haematology-Oncology Unit, Centre Hospitalier Universitaire Vaudois, Service de Pédiatrie, Lausanne; and University Children's Hospital, Zurich, Switzerland.

Submitted April 3, 2009; accepted November 23, 2009; published online ahead of print at www.jco.org on March 1, 2010.

Written on behalf of the Swiss Paediatric Oncology Group.

Supported by Oncosuisse Grant No. KLS 01605-10-2004, the Wyeth Foundation for the Health of Children and Adolescents, and Fellowship Grant No. PA001-117433/1 (G.M.) and Program for Social Medicine. Preventive and Epidemiological Research (PROSPER) Grant No. 3233-069348 (C.K.) from the Swiss National Science Foundation. The Childhood Cancer Registry is supported by the Swiss Paediatric Oncology Group, Kinderkrebshilfe Schweiz, Stiftung für Krebskranke Kinder Regio Basiliensis, Novartis Oncology Switzerland, Interpharma, Axa Wintherthur, GlaxoSmithKline, Amgen, Bristol-Myers Squibb, and numerous other sponsors.

Presented in part at 10th International Conference on Long-Term Complications of Treatment of Children and Adolescents for Cancer, June 6-7, 2008, Niagara-on-the-Lake, Ontario, Canada; 22nd Conference of the European Health Psychology Society, September 9-12, 2008, Bath, United Kingdom; and 40th Annual Meeting of the International Society of Paediatric Oncology, October 2-6, 2008, Berlin, Germany.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

Corresponding author: Gisela Michel, PhD, Institute of Social and Preventive Medicine, University of Bern, Finkenhubelweg 11, 3012 Bern, Switzerland; e-mail: michel@ispm.unibe.ch.

© 2010 by American Society of Clinical Oncology

0732-183X/10/2899-1/\$20.00

DOI: 10.1200/JCO.2009.23.4534

## A B S T R A C T

#### Purpose

To evaluate the degree of psychological distress in adult childhood cancer survivors in Switzerland and to characterize survivors with significant distress.

#### Methods

Childhood cancer survivors who were age younger than 16 years when diagnosed between 1976 and 2003, had survived more than 5 years, and were currently age 20 years or older received a postal questionnaire. Psychological distress was assessed using the Brief Symptom Inventory (BSI). Raw scores were transformed into T scores according to the German norm sample, and the proportion of participants being at increased risk for psychological distress was calculated (case rule:  $T \ge 63$ ). *t* tests and univariable and multivariable logistic regressions were used for statistical analyses.

## Results

One thousand seventy-six survivors (63.3% of eligible survivors, 71.9% of contacted survivors) returned the questionnaire, 987 with complete data on BSI. Comparison with the norm populations showed lower T scores (T < 50) in the Global Severity Index (GSI; T = 46.2), somatization (T = 47.6), obsessive-compulsive tendencies (T = 46.9), and anxiety (T = 48.4). However, more childhood cancer survivors (especially women) had increased distress for GSI (14.4%), interpersonal sensitivity (16.5%), depression (13.4%), aggression (16.9%), and psychotic tendencies (15.6%) than the expected 10% from the norm population. Caseness was associated with female sex, being a single child, older age at study, and self-reported late effects, especially psychological problems.

#### Conclusion

Results show that childhood cancer survivors, on average, have less psychological distress than a norm population but that the proportion of survivors at risk for high psychological distress is disproportionally large. Monitoring psychological distress in childhood cancer survivors may be desirable during routine follow-up, and psychological support should be offered as needed.

J Clin Oncol 28. © 2010 by American Society of Clinical Oncology

## INTRODUCTION

In the past decades, survival rates in childhood cancer have increased and are now reaching 75% to 80%.<sup>1</sup> Somatic late effects have been recognized as an important drawback, and current therapies are aimed at both improving survival rates and reducing adverse outcomes. In contrast, psychological late effects have only recently been considered in largescale studies such as the US Childhood Cancer Survivor Study (US CCSS).<sup>2</sup>

The cancer experience and the adverse somatic late effects of the disease and its treatment may influence psychological well-being and distress of survivors much later in life.<sup>3-5</sup> Especially when diagnosed in adolescence, a time when young people are usually confronted with developmental tasks, such as decisions about their education or gaining independence, survivors may get more disrupted and experience increased psychological distress even long after being cured. Support from family and siblings may help, but recent reports from the US CCSS showed higher levels of depression, anxiety, and somatization in childhood cancer survivors compared with their siblings<sup>6</sup> but similar (in CNS survivors) or lower levels (in survivors of other cancers) than the norm population.<sup>7-10</sup> In these studies, although distress was not associated or only marginally associated with the original diagnosis and treatment, it was more common among survivors with low education or unemployment. Other research showed that survivors who were younger at diagnosis or older at study, were treated with cranial radiation, and experienced relapse or physical limitations were at high risk for psychological distress.<sup>6,11-14</sup>

© 2010 by American Society of Clinical Oncology 1

Information downloaded from jco.ascopubs.org and provided by Universitaetsspital-Bibliothek on March 1, 2010 from

So far, none of the large, population-based, childhood cancer survivor studies has described psychological distress comprehensively. Most previous publications focused on three areas of distress (depression, anxiety, and somatization).<sup>7-9,15</sup> However, a number of smaller studies suggest that other psychological problems, especially paranoid ideation, psychotic tendencies, obsessive-compulsive problems, and post-traumatic stress (PTS), might also be important.<sup>3,11,16-18</sup> Thus, the aims of the present study were to evaluate nine domains of psychological distress in a population-based study of childhood cancer survivors in Switzerland and compare the results with a sample of Swiss psychotherapy patients and to characterize survivors at risk for significant distress.

## METHODS

#### Sample and Procedure

The Swiss Childhood Cancer Registry (SCCR)<sup>19,20</sup> is a population-based registry including all young people diagnosed before age 16 years with leukemia, lymphoma, CNS tumor, malignant solid tumor, or Langerhans cell histiocytosis. The Swiss Childhood Cancer Survivor Study (SCCSS) is a nationwide, long-term, follow-up study of all patients registered at the SCCR who survived for at least 5 years. For the current study, we included all survivors who were age 20 years and older at the time of the study. Ethics approval for this study was provided through the general cancer registry permission of the SCCR (Swiss Federal Expert Commission for Professional Secrecy in Medical Research), and a non obstat statement was obtained from the Cantonal Ethics Committee of Bern.

All survivors received an initial information letter about the study from their former treating institution asking them to report if they did not wish to participate, if their address had changed, or if they required the questionnaire in another language. Two weeks later, all survivors received a questionnaire with a prepaid return envelope. Nonresponders received another questionnaire after 2 months and were then contacted by phone. Questionnaires were provided in three languages (German, French, and Italian).

The comparison sample consisted of all patients between 20 and 49 years old (mean age, 32.5 years; standard deviation [SD], 8.2 years) who received psychotherapy at the University of Bern Outpatient Clinic between January 2000 and May 2009. This sample included patients with a diverse socioeconomic and professional background. The majority was treated for depression or anxiety disorders.

#### Measurements

Baseline demographic information and prospectively collected medical information on diagnosis and treatment were extracted from the SCCR. Diagnosis was classified according to the International Classification of Childhood Cancer (third edition).<sup>21</sup> For the analysis, all major diagnostic groups were used (leukemia, lymphoma, CNS tumors, and other solid tumors). As in other studies, treatment was coded according to whether or not survivors had the following treatments<sup>9</sup>: surgery only, chemotherapy (without radiotherapy but may have had surgery), and radiotherapy (may have had surgery or chemotherapy). In addition, occurrence of bone marrow transplantation or relapse was recorded.

The SCCSS used an extensive questionnaire that was standardized similarly to the questionnaires used in the US and United Kingdom childhood cancer survivor studies.<sup>2,22</sup> Furthermore, we included specific sociodemographic measures for comparison with the Swiss population. The main domains of the questionnaire were quality of life, somatic health, fertility, current medication and health service utilization, psychological distress, health behavior, and socioeconomic information.

Psychological distress was assessed using the Brief Symptom Inventory (BSI).<sup>23,24</sup> The BSI is a widely used and well-validated instrument to screen the following nine domains of distress: somatization, obsessive-compulsive tendencies, interpersonal sensitivity, depression, anxiety, aggression, phobic anxiety, paranoid ideation, and psychotic tendencies. Responses to all 53 items are

summarized in the Global Severity Index (GSI). For a description of the BSI, see the Appendix (online only). For French-speaking survivors, we used a translation previously used in Switzerland.<sup>25</sup> For Italian-speaking survivors, we translated the BSI for this study (sensitivity analyses showed no difference between these groups, and therefore, all were included for analyses). For each item, survivors expressed how much they agree with a statement describing the previous 7 days on a scale from 1 (not at all) to 5 (very much). For survivors who missed up to three items, the scores were computed using the average score of the remaining items as suggested in the manual.<sup>23</sup> Cronbach's  $\alpha$  for our data were as follows: somatization,  $\alpha = .67$ ; obsessive-compulsive tendencies,  $\alpha = .79$ ; interpersonal sensitivity,  $\alpha = .81$ ; depression,  $\alpha = .85$ ; anxiety,  $\alpha = .75$ ; aggression,  $\alpha = .76$ ; phobic anxiety,  $\alpha = .65$ ; paranoid ideation,  $\alpha = .77$ ; psychotic tendencies,  $\alpha = .69$ ; and GSI,  $\alpha = .96$ . Scores from all scales were transformed to T scores (mean = 50; SD = 10) according to the German norm population.<sup>24</sup> We calculated scores according to the overall norm group and separate scores for men and women according to the male and female norm groups. A T score of  $\geq$  63 on any scale corresponds to the 90th percentile in the norm population and indicates a risk for being at significant psychological distress in this area (case rule).<sup>24</sup> Being a case would suggest a further detailed psychodiagnostic examination. Therefore, an indicator for high psychological distress (caseness) was generated for each domain.

Late effects were assessed by asking the survivors whether they experienced any late effects of their cancer or treatment. If answered affirmatively, they further described their problems in open format, and we coded them as somatic only or as psychological problems (including a mixture of psychological and somatic problems). To assess educational achievement and current employment, we used questions from the Swiss Census. The 10 levels of educational achievement were recoded into four levels of schooling (compulsory schooling [ $\leq$  9 years]; vocational training, or schooling for 10 to 13 years; upper secondary education [higher vocational training or college]; and university). Income was recoded into three levels (< 3,000 Swiss francs [CHF] per month, 3,001 to 4,500 CHF per month, and  $\geq$  4,501 CHF per month). Survivors were also asked to list their siblings.



Fig 1. Participants and nonresponders by June 17, 2009. BSI, Brief Symptom Inventory.

2 © 2010 by American Society of Clinical Oncology

JOURNAL OF CLINICAL ONCOLOGY

	Table 1	I. Demograpi	nics and Clin	ical Character	ristics of the	Study Popula	ation			
Demographic or Clinical	Respon Questio	ders to nnaire	Nonres to Ques	ponders tionnaire		Respor B	nders to SI	Nonres to	ponders BSI	
Characteristic	No.	%	No.	%	$P^*$	No.	%	No.	%	Pt
Total	1,076	63.3	623	36.7		987	91.8	88	8.2	
Sex Male Female	595 481	55.3 44.7	365 258	58.6 41.4	.187	535 452	54.2 45.8	60 28	68.2 31.8	.011
Current age, years 20-24.9 25-29.9 ≥ 30	409 313 354	38.0 29.1 32.9	257 157 209	0.0 41.3 25.2 33.5	.196	375 293 319	38.0 29.7 32.3	34 20 34	38.6 22.7 38.6	.311
Age at diagnosis, years 0-4 5-9 10-15	307 285 484	28.5 26.5 45.0	179 187 257	28.7 30.0 41.3	.220	275 263 449	27.9 26.6 45.5	32 21 35	36.4 23.9 39.8	.238
Time since diagnosis, years 5-14 15-19 20-24 ≥ 25	278 285 284 229	25.8 26.5 26.4 21.3	171 156 142 154	27.4 25.0 22.8 24.7	.186	260 263 258 206	26.3 26.6 26.1 20.9	18 22 26 22	20.5 25.0 29.5 25.0	.538
Diagnosis Leukemia Lymphoma CNS tumor Neuroblastoma Retinoblastoma Renal tumor Hepatic tumor Malignant bone tumor Soft tissue sarcoma Germ cell tumor Carcinoma Other malignancy Langerhans cell histiocytosis	394 233 122 37 21 56 5 54 55 34 12 3 48	36.6 21.7 11.3 3.4 2.0 5.2 0.5 5.0 5.1 3.2 1.1 0.3 4.5	189 139 75 28 15 31 3 25 47 25 11 1 29	30.3 22.3 12.0 4.5 2.4 5.0 0.5 4.0 7.5 4.0 1.8 0.2 4.7	.297	364 212 115 32 19 52 5 52 52 27 10 3 42	36.9 21.5 11.7 3.2 1.9 5.3 0.5 5.3 5.3 2.7 1.0 0.3 4.3	29 21 5 2 4 0 2 3 7 2 0 6	33.0 23.9 8.0 5.7 2.3 4.5 0.0 2.3 3.4 8.0 2.3 0.0 6.8	.240
Therapy Surgery only Chemotherapy‡ Radiotherapy§ Bone marrow transplantation Experienced ≥ 1 relapse	94 530 443 43 134	8.7 49.3 41.2 4.0 12.5	68 277 263 21 81	10.9 44.5 42.2 3.4 13.0	.141 .057 .674 .542 .042	87 490 402 39 118	8.8 49.6 40.7 4.0 12.0	7 39 41 4 16	8.0 44.3 46.6 4.5 18.2	.784 .338 .284 .785 .090
Education Compulsory schooling Vocational training Upper secondary education University education						121 424 348 75	12.3 43.0 35.3 7.6	6 2 2 0	6.8 2.3 2.3 0.0	
Employment Full time Part time Still in formation Unemployed						579 195 127 65	58.7 19.8 12.9 6.6	53 11 4 9	60.2 12.5 4.5 10.2	.041
Income of survivor, CHF < 3,001 or unemployed 3,001-4,500 > 4,500						389 279 273	39.4 28.3 27.7	4 2 0	4.5 2.3 0.0	
Late effects No late effects Somatic problems only Psychological problems						595 273 107	60.3 27.7 10.8	47 32 6	53.4 36.4 6.8	.130

NOTE. Two survivors who responded to the questionnaire had to be excluded from analysis because the questionnaire was not usable.

Abbreviations: BSI, Brief Symptom Inventory; CHF, Swiss franc.

\*P values ( $\chi^2$  test) for difference between survivors responding and not responding to the questionnaire of the Swiss Childhood Cancer Survivor Study. †P values ( $\chi^2$  test) for difference between survivors responding and not responding to the Brief Symptom Inventory in the questionnaire of the Swiss Childhood Cancer Survivor Study.

\$Survivor had chemotherapy and may have had surgery but not radiotherapy.

Survivor may have had chemotherapy and surgery.

May include somatic problems.

find y moldade semane presion

## Analysis

Analyses were performed with Stata 10.0 (StataCorp, College Station, TX). The outcomes were the scores of the nine domains of the BSI plus the GSI. Sensitivity analyses were performed using standardized scores

weighted according to age groups of the German population norm. For descriptive analyses and comparison with the population norm (mean T score = 50; case index T  $\ge$  63), we used the T scores normed for the overall population and separately for male and female population norms. We used *t* 

© 2010 by American Society of Clinical Oncology 3

tests and binomial proportion tests to detect mean differences to the T norm score of 50 and the expected proportion of 10% of survivors at risk for significant distress. We used *t* tests to compare the raw mean scores of psychotherapy patients and distressed survivors. For the remaining analyses, the case indices for each domain were used (according to the overall population). Univariable logistic regression analyses were used for each scale separately to analyze associations with caseness. Multivariable logistic regression was used including all variables significant at the 5% level in the univariable regressions. We used Holm's correction to adjust for multiple testing.<sup>26</sup> Holm *P* values were determined to be significant at the 5% level.

## RESULTS

In the SCCR, 2,919 survivors were eligible for the SCCSS, of whom 1,699 were  $\geq$  20 years old (Fig 1). Of the 1,497 survivors who we could trace, 1,076 replied (response rate: 63.3% of eligible survivors; 71.9% of traced survivors). Nonresponders were more likely to have experienced a relapse. The BSI could be evaluated in 987 survivors (87 survivors did not fill in any item and one survivor filled in three items). Three survivors missed three items, eight survivors missed two items, and 49 survivors missed one item. Characteristics of the 987 survivors with BSI information, compared with nonresponders, are listed in Table 1. The mean age of survivors at study was 27.9 years (SD = 6.0 years; range, 20.0 to 49.1 years); mean age at diagnosis was 8.4 years (SD = 4.7 years; range, 0.0 to 16.0 years); and mean time since diagnosis was 19.5 years (SD = 6.5 years; range, 5.8 to 37.9 years).

### **Comparison With Norm Population**

Sensitivity analyses showed similar results using weighted and unweighted data. For simplicity, we present unweighted results. Childhood cancer survivors had lower T scores than the norm population for GSI, somatization, obsessive-compulsive tendencies, and anxiety (Table 2). However, more childhood cancer survivors (especially females) were at risk for significant psychological distress (T score  $\geq 63$ ) in GSI, interpersonal sensitivity, depression, aggression, and psychotic tendencies than expected from the norm population (Table 2). Two hundred forty-three survivors (24.6%; 95% CI, 21.9% to 27.3%) were cases on two or more domain scales or on the GSI (for sex-specific norms: 98 men [18.3%; 95% CI, 15.0% to 21.6%]; 127 women [28.1%; 95% CI, 24.0% to 32.2%]).

## **Comparison With Psychotherapy Patients**

Data for 554 patients from the psychotherapy outpatient clinic were available (males, n = 252). Survivors identified as having high distress in the nine domains and the GSI had higher or similar mean scores as the psychotherapy patient sample (Table 3).

## **Demographic Characteristics**

Regarding GSI, women (odds ratio [OR] = 1.88), single children (OR = 2.09), and immigrants (OR = 1.96) were almost twice as likely to report high distress than men, those with siblings, and those born in Switzerland. Survivors older than 30 years were also at higher risk for being cases on the GSI (OR = 1.77). There was no association with education, employment, or income (Table 4). Associations were fairly similar for all domains of the BSI (Fig 2; Appendix Tables A1 to A9, online only).

## Medical Characteristics

There was no association between GSI and cancer diagnosis, treatment, relapse, or time since diagnosis (Table 4). Results were

similar for all domains (Appendix Tables A1 to A9). Survivors who were older at diagnosis were more likely to have high distress on the GSI than those between 0 and 4 years old at diagnosis (OR = 1.74). Self-reported late effects, especially if including psychological problems (or a mixture of psychological and somatic problems), were associated with high distress in all domains (somatic problems: OR between 1.71 and 2.67; psychological problems: OR between 3.72 and 7.66; Fig 2, Appendix Tables A1 to A9).

Multivariable logistic regression confirmed increased risk of being cases in the GSI for women, single children, survivors who were older at study, and survivors reporting somatic or psychological late effects (Table 4). Again, results were similar for all domains of the BSI (Appendix Tables A1 to A9).

#### DISCUSSION

To our knowledge, this is the first report evaluating nine dimensions of psychological distress in a representative national cohort study of childhood cancer survivors. Overall results were reassuring, with the majority of survivors reporting low levels of distress. However, one fourth of survivors, instead of the expected 10% in the norm population, reported distress to a degree that makes closer observation and potentially counseling worthwhile. Comparisons with psychotherapy patients indicated that survivors' distress is clinically significant.

Interestingly, mean distress in the overall sample was lower than population norms, whereas a larger proportion of survivors could be considered cases with psychological distress compared with the norm population. This suggests that survivors have either no/very low distress or high distress. Recent studies suggested both outcomes are common (eg, PTS and post-traumatic growth [PTG]) and may even occur together.<sup>27,28</sup> Future studies should include measures of PTS and PTG when assessing psychological distress. Personality characteristics such as optimism might also influence how survivors deal with the cancer experience and might influence distress later on.<sup>29</sup>

Our results confirm previous findings of increased interpersonal sensitivity, aggression, and psychotic tendencies in survivors.<sup>3,16</sup> This may reflect that the cancer experience still makes survivors feel different from peers and supports previous research findings of alienation and loneliness in social contacts in survivors.<sup>30</sup>

The only directly comparable study is the US CCSS, which, however, included only three domains (BSI-18). In contrast to this study, we found higher proportions of cases for the domain of depression and the GSI, as well as interpersonal sensitivity, aggression, and psychotic tendencies. The proportion of survivors classified as cases on the GSI, for instance, was higher in our sample (men: 10.8%; women: 18.6%) than in the US CCSS (men: 8.6% [95% CI, 7.7% to 9.5%]; women: 12.4% [95% CI, 11.3% to 13.5%]).15 They found a relatively low proportion of survivors with significant psychological distress in at least two domains or in the GSI of the BSI-18 (7.4% of men [95% CI, 6.7% to 8.2%] and 9% of women [95% CI, 8.1% to 9.9%]),<sup>10</sup> compared with our findings of 11.6% of men (95% CI, 8.9% to 14.3%) and 18.8% of women (95% CI, 15.2% to 22.4%) with significant distress in the BSI (only the BSI-18 domains or GSI considered). One reason for this difference might be that we included a nationally representative sample, whereas the US CCSS only included patients treated in major pediatric cancer centers.<sup>2</sup>

JOURNAL OF CLINICAL ONCOLOGY

Information downloaded from jco.ascopubs.org and provided by Universitaetsspital-Bibliothek on March 1, 2010 from

<sup>4 © 2010</sup> by American Society of Clinical Oncology

	<i>t</i> Test for Diff	erence to $T = 50$ (ty	vo-sided)	Test for Diff	erence of Proportior Expected	n of Cases (T score and 10% †	≥ 63) to
BSI Domain*	Mean t Score	95% CI	P	No. of Cases	% of Cases	95% CI	Р
Somatization							
All	47.6	47.1 to 48.2	< .001‡	80	8.1	6.4 to 9.8	.047
Men	47.3	46.6 to 48.0	< .001‡	36	6.7	4.6 to 8.9	.012
Women	48.4	47.5 to 49.3	< .001‡	35	7.7	5.3 to 10.2	.110
Obsessive-compulsive							
All	46.9	46.2 to 47.6	< .001‡	104	10.5	8.6 to 12.5	.574
Men	46.5	45.6 to 47.3	< .001‡	43	8.0	5.7 to 10.3	.130
Women	47.8	46.7 to 48.9	< .001‡	61	13.5	10.0 to 16.6	.013
Interpersonal sensitivity							
All	49.1	48.4 to 49.8	.009	163	16.5	14.0 to 18.8	< .001‡
Men	48.3	47.4 to 49.1	< .001‡	55	10.3	7.7 to 12.9	.829
Women	49.9	48.8 to 51.0	.871	72	15.9	13.0 to 19.3	< .001‡
Depression							
All	49.4	48.7 to 50.0	.053	132	13.4	11.0 to 15.5	< .001‡
Men	49.9	49.1 to 50.7	.826	57	10.7	8.0 to 13.3	.614
Women	49.6	48.6 to 50.6	.426	75	16.6	13.0 to 20.0	< .001‡
Anxiety							
All	48.4	47.7 to 49.0	<.001‡	126	12.8	11.0 to 14.8	.004
Men	48.3	47 4 to 49 1	< 001‡	59	11.0	8 4 to 13 7	428
Women	48.5	47.5 to 49.6	.008	54	12.0	9.0 to 14.9	.168
Aggression							
All	49.9	49.3 to 50.6	.853	167	16.9	15.0 to 19.3	< .001‡
Men	50.3	49.5 to 51.2	442	82	15.3	12.0 to 18.4	< 001±
Women	50.3	49.2 to 51.3	618	85	18.8	15.0 to 22.4	< 001‡
Phobic anxiety	0010	1012 10 0 110	1010		1010	1010 10 2211	1.0011
All	50.5	50 0 to 51 1	053	101	10.2	8.3 to 12.1	807
Men	49.8	49.1 to 50.5	548	41	77	5.4 to 9.9	072
Women	50.8	49.9 to 51.6	092	60	13.3	10.0 to 16.4	020
Paranoid ideation	00.0	10.0 10 01.0	.002	00	10.0	10.0 10 10.1	.020
	49 5	48 9 to 50 1	129	115	11 7	9.6 to 13.7	084
Men	/9.1	18.3 to 49.8	019	51	95	7.0 to 12.0	719
Women	49.1 79.9	48.9 to 50.9	.010	6/	1/1 2	11.0 to 17.4	., 13
Psychotic tendencies	-0.0	40.0 10 00.0	.001		14.2	11.0 to 17.4	.000
	50.7	50 1 to 51 3	025	154	15.6	13.0 to 17.9	< 001+
Men	/9.7	49.0 to 50.4	.020	38	7.1	19 to 93	026
Wemen	4J.7 51 1	40.0 to 50.4	.430	94	19.6	4.0 to 0.0	- 001+
Global Severity Index	51.1	30.1 10 32.1	.020	04	10.0	10.0 10 22.2	< .001+
	16.2	153 to 171	< 001+	1/12	1//	12 0 to 16 6	< 001+
Mon	40.2	40.0 10 47.1	< .001+	14Z	14.4	9.2 to 12 E	< .001+ 517
Maman	40.4	44.3 10 40.5	< .001+	04	10.0	0.2 LU 13.5	.001+
vvomen	4/.Z	45.8 10 48.6	< .001+	84	10.0	15.01022.2	< .UUIŦ

Abbreviation: BSI, Brief Symptom Inventory.

\*All survivors, N = 987; men, n = 535; women, n = 452.

†To test the difference between the proportion of cases compared with the expected 10%, we used an exact two-sided test based on the binomial distribution. +Holm's correction was used to determine statistical significance corresponding to a 5% level while taking into consideration multiple comparisons: P < .0026 for t test for difference to 50 and P < .0028 for difference to 10%.

Characteristics of Swiss survivors with distress were similar to those described in the US CCSS. Medical characteristics, including diagnosis and treatment, were not associated with distress, whereas some sociodemographic characteristics were associated with distress.<sup>7-9,15,31</sup> Similar to studies in the general population,<sup>32,33</sup> women and immigrants were at almost double the risk for psychological distress. Immigration is often a stressful event and poses additional risk for psychological distress.<sup>34</sup> However, most immigrant survivors (75.9%; 95% CI, 64.5% to 87.3%) were able to adjust well and did not show high risks for psychological distress. In contrast to findings from the US CCSS, we found no association with unemployment or low education for the GSI, although there was a trend in this direction for unemployment. Medical insurance is compulsory in Switzerland and provided by the state when unaffordable by individuals. Therefore, health care (eg, follow-up care after childhood cancer) is available to everyone, which might attenuate socioeconomic differentials in mental health.

A new finding is that survivors who had siblings reported less distress than those without siblings. This is important for parents of children with cancer, who often worry about having to share their love

© 2010 by American Society of Clinical Oncology 5

		Survivors			Psychotherapy Pa	tients		
BSI Domain	No.	Mean Score	95% CI	No.	Mean Score	95% CI	Т	Р
All								
Somatization	80	0.96	0.89 to 1.02	554	0.73	0.67 to 0.80	6.69	< .00
Obsessive-compulsive	104	1.59	1.51 to 1.67	553	1.40	1.32 to 1.47	4.94	< .00
Interpersonal sensitivity	163	1.54	1.45 to 1.64	553	1.49	1.41 to 1.58	1.10	.273
Depression	132	1.30	1.20 to 1.40	553	1.39	1.31 to 1.46	-1.81	.072
Anxiety	126	1.22	1.14 to 1.30	553	1.17	1.10 to 1.24	1.24	.218
Aggression	167	1.22	1.14 to 1.30	554	0.99	0.93 to 1.05	5.65	< .00
Phobic anxiety	101	0.92	0.83 to 1.00	554	0.73	0.66 to 0.80	4.41	< .00
Paranoid ideation	115	1.48	1.38 to 1.59	553	0.89	0.83 to 0.96	11.33	< .002
Psychotic tendencies	154	0.94	0.86 to 1.01	554	0.96	0.90 to 1.02	-0.60	.552
Global Severity Index	142	1.01	0.95 to 1.07	554	1.07	1.02 to 1.12	-1.96	.052
Male								
Somatization	36	0.81	0.72 to 0.89	252	0.59	0.50 to 0.67	5.10	< .00
Obsessive-compulsive	43	1.53	1.42 to 1.63	252	1.38	1.27 to 1.49	2.90	.000
Interpersonal sensitivity	55	1.49	1.35 to 1.63	251	1.37	1.25 to 1.49	1.70	.09
Depression	57	1.13	1.03 to 1.24	251	1.36	1.24 to 1.48	-4.39	< .00
Anxiety	59	1.04	0.98 to 1.10	251	1.12	1.02 to 1.22	-2.51	.01
Aggression	82	1.13	1.04 to 1.23	252	0.90	0.81 to 0.99	4.87	< .00
Phobic anxiety	41	0.87	0.76 to 0.98	252	0.68	0.58 to 0.78	3.55	.00
Paranoid ideation	51	1.36	1.25 to 1.47	251	0.89	0.79 to 0.98	8.49	< .00
Psychotic tendencies	38	1.03	0.93 to 1.14	252	0.95	0.86 to 1.05	1.59	.12
Global Severity Index	58	0.90	0.83 to 0.96	252	1.02	0.94 to 1.09	-3.71	.00
Female								
Somatization	35	1.13	1.01 to 1.24	301	0.86	0.76 to 0.95	4.75	< .00
Obsessive-compulsive	61	1.64	1.53 to 1.75	300	1.41	1.31 to 1.51	4.12	< .00
Interpersonal sensitivity	72	1.85	1.71 to 2.00	301	1.59	1.49 to 1.70	3.55	.00
Depression	75	1.43	1.28 to 1.58	301	1.40	1.29 to 1.51	0.39	.698
Anxiety	54	1.51	1.37 to 1.65	301	1.21	1.12 to 1.31	4.38	< .00
Aggression	85	1.31	1.18 to 1.43	301	1.06	0.97 to 1.14	3.81	< .00
Phobic anxiety	60	0.95	0.83 to 1.07	301	0.77	0.67 to 0.87	2.93	.00
Paranoid ideation	64	1.58	1.42 to 1.74	301	0.89	0.80 to 0.98	8.48	< .00
Psychotic tendencies	84	1.02	0.91 to 1.14	301	0.96	0.87 to 1.05	1.07	.28
Global Severity Index	84	1.09	0.99 to 1.18	301	1 12	1 05 to 1 19	-0.73	.46

and attention between a severely ill child and a healthy sibling. Sharing the difficult experience with a sibling might help a child coping with problems.

In contrast to results from the US CCSS, the risk for significant distress in the GSI was higher in survivors older than 10 years at diagnosis. Adolescents, in contrast to younger children, will fully understand the life-threatening aspect of the disease, at a time of life when they are confronted with other important developmental tasks.<sup>35-37</sup>

Self-reported somatic late effects were strongly associated with psychological distress in our study. Not unexpectedly, survivors acknowledging psychological problems as late effects were identified as having more than six times the odds of distress of survivors not reporting late effects.

A limitation of the study is the lack of Swiss norms for the BSI, and we do not know how accurate the German norms (established between 1995 and 1997) fit the current Swiss population. However, our comparisons of survivors with high distress with a sample of patients from a psychotherapy outpatient clinic showed that survivors had significantly higher raw mean scores (higher distress) than psychotherapy patients in most domains. This supports the validity of the use of the German norms to identify survivors with high psychological distress in a Swiss sample. Age-matched norms are not currently available for the German BSI, but sensitivity analyses using standardization according to the age groups in the norm population suggest no major difference to the presented data.

Self-selection of survivors and the self-report measure used might bias results. A detailed clinical interview may result in more accurate assessment of psychological distress. However, the BSI has been shown to be a valid screening instrument in childhood cancer survivors.<sup>38</sup> Highly distressed survivors may choose not to fill out the questionnaire, resulting in an overly positive sample with low distress. This might also be the case in norm populations, and the response rate of 71.9% of contacted survivors was similar to other studies in the United States and United Kingdom,<sup>2,22</sup> suggesting a high representativeness of our sample. The clinical significance of the cutoff score (T  $\ge$  63)<sup>24</sup> will need to be determined. A recent study supported the use of a lower cutoff score for the BSI-18<sup>39</sup> in childhood cancer survivors (T  $\ge$  50).<sup>38</sup> Thus, we may have underestimated the true prevalence of distress in Swiss survivors. Treatment has only been crudely coded into surgery, chemotherapy, or

6 © 2010 by American Society of Clinical Oncology

JOURNAL OF CLINICAL ONCOLOGY

Information downloaded from jco.ascopubs.org and provided by Universitaetsspital-Bibliothek on March 1, 2010 from

	and Potential	Explanat	ory Facto	rs by Univariable	and Mul	tivariable Logistic	Regression	oovonty		
			Cas	ses	l	Inivariable Regres	sion	M	ultivariable Regre	ssion
Factor	No. of Survivors	No.	%	95% CI	OR	95% CI	Р	OR	95% CI	Р
Sex	505		10.0		4.00			4.00		
Male	535	58	10.8	8.2 to 13.5	1.00	4 04 4 0 00	004	1.00	4.00 + 0.04	000
Female	452	84	18.6	15.0 to 22.2	1.88	1.31 to 2.69	.001	1.79	1.22 to 2.64	.003
Current age, years	070	4.1	11.0	7.0 += 14.0	1 00			1 00		
20-24	3/3	41	11.0	7.8 to 14.2	1.00	0.01 += 0.07	100	1.00	1 01 to 0 07	044
25-29	292	44	15.1	11.0 to 19.2	1.44	0.91 to 2.27	.120	1.05	1.01 to 2.67	.044
$\leq 30$	318	57	17.9	13.7 to 22.1	1.77	1.15 10 2.73	.010	1.90	1.18 10 3.04	.008
Siblings	000	110	10.0	11 1 +- 15 5	1 00			1 00		
Yes	888	118	13.3	11.1 to 15.5	1.00	1 07 to 0 44	004	1.00	1 40 to 4 22	001
INO	99	24	Z4.Z	15.8 to 32.7	2.09	1.27 to 3.44	.004	2.53	1.48 to 4.32	.001
Immigration status	007	100	10.0	11 7+- 10 1	1 00			1 00		
Native Swiss	927	129	13.9	11.7 to 16.1	1.00	1 00 to 2 70	040	1.00	1 OF to 4 20	007
Immigrant	54	13	24.1	12.7 to 35.5	1.96	1.02 to 3.76	.043	2.11	1.05 to 4.26	.037
	010	107	10.0	11 7+- 10 0	1 00					
Other degree	912	127	13.9	11.7 to 16.2	1.00	0.05 +- 0.00	150			
University degree	/5	15	20.0	10.9 to 29.1	1.55	0.85 to 2.80	.152			
Employment	001	400	110	44 7 4 40 0	1 00					
Employed	901	126	14.0	11.7 to 16.2	1.00	0.01 += 0.14	000			
	65	14	21.5	11.5 to 31.5	1.69	0.91 to 3.14	.098			
Income, CHF	000	00	45.4	44.0 + 40.0	1 00					
< 3,001	389	60	15.4	11.8 to 19.0	1.00	0.04 + 4.45	705			
3,001-4,500	279	41	14.7	10.5 to 18.8	0.94	0.61 to 1.45	.795			
> 4,500	273	30	11.0	7.3 to 14.7	0.68	0.42 to 1.08	.103			
Age at diagnosis, years	075									
0-4	275	28	10.2	6.6 to 13.8	1.00	0.04 + 0.05	001	1.00	0.00 0.005	100
5-9	263	40	15.2	10.9 to 19.5	1.58	0.94 to 2.65	.081	1.53	0.88 to 2.65	.129
10-15	449	/4	16.5	13.0 to 19.9	1.74	1.09 to 2.77	.019	1.31	0.79 to 2.16	.295
Time since diagnosis, years	000		15.0	44.0 + 00.0	1 00					
5-14	260	41	15.8	11.3 to 20.2	1.00	0 50 4 50	705			
15-19	263	39	14.8	10.5 to 19.1	0.93	0.58 to 1.50	./65			
20-24	258	29	11.2	7.4 to 15.1	0.68	0.41 to 1.13	.133			
≥ 25	206	33	16.0	11.0 to 21.0	1.02	0.62 to 1.68	.941			
Diagnosis										
Leukemia	364	49	13.5	10.0 to 17.0	1.00	0.57.4.55				
Lymphoma	212	27	12.7	8.2 to 17.2	0.94	0.57 to 1.55	.804			
CNS tumor	115	20	17.4	10.5 to 24.3	1.35	0.77 to 2.39	.297			
Other tumor	294	46	15.6	11.5 to 19.8	1.19	0.77 to 1.84	.428			
Ireatment										
Surgery	490	60	12.2	9.3 to 15.1	1.00	0.00.005				
Chemotherapy*	402	66	16.4	12.8 to 20.0	1.41	0.96 to 2.05	.076			
Radiotherapy†	87	15	17.2	9.3 to 25.2	1.49	0.80 to 2.77	.204			
BMT										
No	948	136	14.3	12.1 to 16.6	1.00					
Yes	39	6	15.4	4.1 to 26.7	1.09	0.45 to 2.64	.856			
Relapse										
Yes	869	126	14.5	12.2 to 16.8	1.00					
No	118	16	13.6	7.4 to 19.7	0.92	0.53 to 1.62	.785			
Late effects			c -	0.5.1.1.1						
No late effects	595	52	8.7	6.5 to 11.0	1.00			1.00		
Somatic problems only	273	46	16.8	12.4 to 21.3	2.12	1.38 to 3.24	.001	2.00	1.29 to 3.11	.002
Psychological problems‡	107	41	38.3	29.1 to 47.5	6.49	4.00 to 10.51	< .001	6.74	4.06 to 11.17	< .001

Abbreviations: BSI, Brief Symptom Inventory; OR, odds ratio; CHF, Swiss franc; BMT, bone marrow transplantation.

\*Survivor had chemotherapy and may have had surgery but no radiotherapy.

†Survivor may have had chemotherapy and surgery.

‡May include somatic problems.

radiotherapy. Future studies might profit from including more detailed information.

Major strengths of this study are the population-based sample and the use of the complete BSI with nine domains. With demographic and medical variables from the SCCR, we were able to include prospectively assessed predictors into our analyses. The comparison with psychotherapy patients supported the clinical significance of our findings. A future study may profit from assessing socioeconomic

© 2010 by American Society of Clinical Oncology 7



Fig 2. Proportions of cases ( $T \ge 63$ ) in different survivor groups according to (A) sex, (B) siblings, (C) immigration status, (D) employment status, and (E) self-reported late effects. BSI, Brief Symptom Inventory; GSI, Global Severity Index; CH, Switzerland.

predictors prospectively and independently from the assessment of the BSI to establish a causal pathway for the manifestation of psychological distress.

Current socioeconomic and psychological contexts may be more important for current psychological distress than earlier medical characteristics such as diagnosis, treatment, and relapse. Although follow-up care is certainly well organized in the first years after diagnosis, established long-term care including psychosocial support is still lacking in Switzerland. We can conclude that it is desirable to monitor psychological distress in childhood cancer survivors during follow-up care appointments even years after they have been cured. Routine psychological screening has been shown to be feasible in

8 © 2010 by American Society of Clinical Oncology

JOURNAL OF CLINICAL ONCOLOGY

Information downloaded from jco.ascopubs.org and provided by Universitaetsspital-Bibliothek on March 1, 2010 from

survivor clinics, and it has been suggested that incidence of psychological distress in survivors attending follow-up may be even higher than in the general survivor population.<sup>11</sup> A close collaboration with key workers in the psychosocial area may provide an optimal environment to immediately deal with imminent psychosocial problems.

## AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

The author(s) indicated no potential conflicts of interest.

## REFERENCES

1. Gatta G, Zigon G, Capocaccia R, et al: Survival of European children and young adults with cancer diagnosed 1995-2002. Eur J Cancer 45:992-1005, 2009

2. Robison LL, Mertens AC, Boice JD, et al: Study design and cohort characteristics of the Childhood Cancer Survivor Study: A multi-institutional collaborative project. Med Pediatr Oncol 38:229-239, 2002

**3.** Wiener L, Battles H, Bernstein D, et al: Persistent psychological distress in long-term survivors of pediatric sarcoma: The experience at a single institution. Psychooncology 15:898-910, 2006

**4.** Maurice-Stam H, Oort FJ, Last BF, et al: Longitudinal assessment of health-related quality of life in preschool children with non-CNS cancer after the end of successful treatment. Pediatr Blood Cancer 50:1047-1051, 2008

5. Patenaude AF, Kupst MJ: Psychosocial functioning in pediatric cancer. J Pediatr Psychol 30:9-27, 2005

6. Zeltzer LK, Recklitis C, Buchbinder D, et al: Psychological status in childhood cancer survivors: A report from the Childhood Cancer Survivor Study. J Clin Oncol 27:2396-2404, 2009

7. Zebrack BJ, Gurney JG, Oeffinger K, et al: Psychological outcomes in long-term survivors of childhood brain cancer: A report from the Childhood Cancer Survivor Study. J Clin Oncol 22:999-1006, 2004

8. Zebrack BJ, Zeltzer LK, Whitton J, et al: Psychological outcomes in long-term survivors of childhood leukemia, Hodgkin's disease, and non-Hodgkin's lymphoma: A report from the Childhood Cancer Survivor Study. Pediatrics 110:42-52, 2002

9. Zebrack BJ, Zevon MA, Turk N, et al: Psychological distress in long-term survivors of solid tumors diagnosed in childhood: A report from the Childhood Cancer Survivor Study. Pediatr Blood Cancer 49:47-51, 2007

**10.** Recklitis CJ, Parsons SK, Shih MC, et al: Factor structure of the Brief Symptom Inventory–18 in adult survivors of childhood cancer: Results from the Childhood Cancer Survivor Study. Psychol Assess 18:22-32, 2006

**11.** Recklitis C, O'Leary T, Diller L: Utility of routine psychological screening in the childhood cancer survivor clinic. J Clin Oncol 21:787-792, 2003

**12.** Glover DA, Byrne J, Mills JL, et al: Impact of CNS treatment on mood in adult survivors of child-

hood leukemia: A report from the Children's Cancer Group. J Clin Oncol 21:4395-4401, 2003

**13.** Elkin TD, Phipps S, Mulhern RK, et al: Psychological functioning of adolescent and young adult survivors of pediatric malignancy. Med Pediatr Oncol 29:582-588, 1997

**14.** Hill JM, Kornblith AB, Jones D, et al: A comparative study of the long term psychosocial functioning of childhood acute lymphoblastic leukemia survivors treated by intrathecal methotrexate with or without cranial radiation. Cancer 82:208-218, 1998

**15.** Zeltzer LK, Lu Q, Leisenring W, et al: Psychosocial outcomes and health-related quality of life in adult childhood cancer survivors: A report from the Childhood Cancer Survivor Study. Cancer Epidemiol Biomarkers Prev 17:435-446, 2008

 Kornblith AB, Herndon JE II, Zuckerman E, et al: Comparison of psychosocial adaptation of advanced stage Hodgkin's disease and acute leukemia survivors. Ann Oncol 9:297-306, 1998

17. Rusiewicz A, DuHamel KN, Burkhalter J, et al: Psychological distress in long-term survivors of hematopoietic stem cell transplantation. Psychooncology 17:329-337, 2008

**18.** Hobbie WL, Stuber M, Meeske K, et al: Symptoms of posttraumatic stress in young adult survivors of childhood cancer. J Clin Oncol 18:4060-4066, 2000

**19.** Michel G, von der Weid NX, Zwahlen M, et al: The Swiss Childhood Cancer Registry: Rationale, organisation and results for the years 2001-2005. Swiss Med Wkly 137:502-509, 2007

**20.** Michel G, von der Weid NX, Zwahlen M, et al: Incidence of childhood cancer in Switzerland: The Swiss Childhood Cancer Registry. Pediatr Blood Cancer 50:46-51, 2008

**21.** Steliarova-Foucher E, Stiller C, Lacour B, et al: International Classification of Childhood Cancer, third edition. Cancer 103:1457-1467, 2005

**22.** Hawkins MM, Lancashire ER, Winter DL, et al: The British Childhood Cancer Survivor Study: Objectives, methods, population structure, response rates and initial descriptive information. Pediatr Blood Cancer 50:1018-1025, 2008

**23.** Derogatis LR: Brief Symptom Inventory (BSI): Administration, Scoring, and Procedures Manual (ed 3). Minneapolis, MN, Minneapolis National Computer Services, 1993

24. Franke GH: BSI, Brief Symptom Inventory, von L.R. Derogatis – Deutsches Manual. Göttingen, Germany, Beltz Test Gesellschaft, 2000

25. Perrez M, Schoebi D, Wilhelm P: How to assess social regulation of stress and emotions in daily family life? A computer-assisted family self-

## AUTHOR CONTRIBUTIONS

**Conception and design:** Gisela Michel, Nicolas X. von der Weid, Claudia E. Kuehni

Financial support: Gisela Michel, Nicolas X. von der Weid, Claudia E. Kuehni Administrative support: Gisela Michel

Collection and assembly of data: Cornelia E. Rebholz

Data analysis and interpretation: Gisela Michel, Claudia E. Kuehni Manuscript writing: Gisela Michel, Cornelia E. Rebholz, Nicolas X. von der Weid, Eva Bergstraesser, Claudia E. Kuehni

Final approval of manuscript: Gisela Michel, Cornelia E. Rebholz, Nicolas X. von der Weid, Eva Bergstraesser, Claudia E. Kuehni

> monitoring system (FASEM-C). Clin Psychol Psychother 7:326-339, 2000

> **26.** Aickin M, Gensler H: Adjusting for multiple testing when reporting research results: The Bonferroni vs Holm methods. Am J Public Health 86: 726-728, 1996

**27.** Rourke MT, Hobbie WL, Schwartz L, et al: Posttraumatic stress disorder (PTSD) in young adult survivors of childhood cancer. Pediatr Blood Cancer 49:177-182, 2007

**28.** Barakat LP, Alderfer MA, Kazak AE: Posttraumatic growth in adolescent survivors of cancer and their mothers and fathers. J Pediatr Psychol 31:413-419, 2006

**29.** Michel G, Taylor N, Absolom K, et al: Benefit finding in survivors of childhood cancer and their parents: Further empirical support for the Benefit Finding Scale for Children (BFSC). Child Care Health Dev [epub ahead of print on November 30, 2009]

**30.** Mackie E, Hill J, Kondryn H, et al: Adult psychosocial outcomes in long-term survivors of acute lymphoblastic leukaemia and Wilms' tumour: A controlled study. Lancet 355:1310-1314, 2000

**31.** Hudson MM, Mertens AC, Yasui Y, et al: Health status of adult long-term survivors of childhood cancer: A report from the Childhood Cancer Survivor Study. JAMA 290:1583-1592, 2003

**32.** Gilbar O, Ben-Zur H: Adult Israeli community norms for the Brief Symptom Inventory (BSI). Int J Stress Manage 9:1-10, 2002

**33.** Ryan C: British outpatient norms for the Brief Symptom Inventory. Psychol Psychother 80:183-191, 2007

**34.** Dalgard OS, Thapa SB, Hauff E, et al: Immigration, lack of control and psychological distress: Findings from the Oslo Health Study. Scand J Psychol 47:551-558, 2006

**35.** Zebrack BJ, Yi J, Petersen L, et al: The impact of cancer and quality of life for long-term survivors. Psychooncology 17:891-900, 2008

**36.** Evan EE, Zeltzer LK: Psychosocial dimensions of cancer in adolescents and young adults. Cancer 107:1663-1671, 2006

**37.** Schrag NM, McKeown RE, Jackson KL, et al: Stress-related mental disorders in childhood cancer survivors. Pediatr Blood Cancer 50:98-103, 2008

**38.** Recklitis CJ, Rodriguez P: Screening childhood cancer survivors with the Brief Symptom Inventory-18: Classification agreement with the Symptom Checklist-90-Revised. Psychooncology 16:429-436, 2007

**39.** Derogatis LR: BSI-18 Administration, Scoring, and Procedures Manual. Minneapolis, MN, National Computer Services, 2000

## Acknowledament

We thank the University of Bern Outpatient Clinic for the provision of comparison data of a sample of psychotherapy patients. The following are members of the Swiss Paediatric Oncology Group Scientific Committee: PD M. Beck, MD, Popovic, Lausanne; U. Caflisch, MD, Lucerne; J. Greiner, MD, St Gallen; H. Hengartner, MD, St Gallen; Prof A. Hirt, MD, Bern; R. Angst, MD, Aarau; Prof M. Paulussen, MD, Basel; PD T. Kuehne, MD, Basel; Prof F. Niggli, MD, Zurich; PD M. Grotzer, MD, Zurich; P. Brazzola, MD, Ticino; L. Nobile Buetti, MD, Ticino; and PD A.H. Ozsahin, MD, Geneva.

## Appendix

## Description of the Brief Symptom Inventory

Psychological distress was assessed using the Brief Symptom Inventory (BSI).<sup>23</sup> The BSI is a widely used and well-validated instrument to screen nine domains of psychological distress. Responses to all 53 items are summarized in the Global Severity Index (GSI). Each item expresses a statement on which survivors had to respond how much they suffered from the problem described during the previous 7 days (scores range from 1 = not at all to 5 = very much).

Scores from all scales can be transformed to T scores (mean = 50; standard deviation = 10) according to the German norm population.<sup>24</sup> Norm scores are available for an adult population (n = 600), separately for men (n = 300) and women (n = 300), and for a student population (n = 589). The German adult norm population was assessed between 1995 and 1997 using a snowballing strategy and stratified according to their educational background. The age groups included 280 individuals age younger than 30 years, 159 individuals between 30 and 40 years old, and 161 individuals age older than 40 years. Currently, there are no specific norms for Switzerland available, and studies in the Swiss population usually use the German norms.

A T score of 63 or more on any scale corresponds to the 90th percentile in the norm population, and having a T score of  $\geq$  63 on the GSI scale or any two other scales indicates clinically significant psychological distress (case rule).<sup>24</sup> Being a case would suggest a further detailed psychodiagnostic examination.

			Cas	es	U	nivariable Regres	sion	M	ultivariable Regre	ssion
Factor	No. of Survivors	No.	%	95% CI	OR	95% CI	Р	OR	95% CI	Р
ex	505			07.00				4.00		
Male	535	24	4.5	2.7 to 6.2	1.00			1.00	1 - 1	
Female	452	56	12.4	9.4 to 15.4	3.01	1.83 to 4.94	< .001	2.95	1.74 to 5.01	< .00
urrent age, years	070									
20-24	3/3	29	7.8	5.1 to 10.5	1.00					
25-29	292	18	6.2	3.4 to 8.9	0.78	0.42 to 1.43	.422			
≥ 30	318	32	10.1	6.8 to 13.4	1.33	0.78 to 2.25	.292			
iblings										
Yes	888	69	7.8	6.0 to 9.5	1.00	0.70.004	054			
No	99	11	11.1	4.9 to 17.3	1.48	0.76 to 2.91	.251			
nmigration status										
Native Swiss	927	74	8.0	6.2 to 9.7	1.00					
Immigrant	54	6	11.1	2.7 to 19.5	1.44	0.6 to 3.48	.417			
ducation										
Other degree	912	73	8.0	6.2 to 9.8	1.00					
University degree	75	7	9.3	2.7 to 15.9	1.18	0.52 to 2.67	.686			
mployment										
Employed	901	68	7.5	5.8 to 9.3	1.00			1.00		
Unemployed	65	11	16.9	7.8 to 26.0	2.5	1.25 to 4.99	.010	1.79	0.84 to 3.81	.128
ncome, CHF										
< 3,001	389	32	8.2	5.5 to 11.0	1.00					
3,001-4,500	279	23	8.2	5.0 to 11.5	1.00	0.57 to 1.75	.994			
> 4,500	273	18	6.6	3.6 to 9.5	0.79	0.43 to 1.43	.435			
Age at diagnosis, years										
0-4	275	23	8.4	5.1 to 11.6	1.00					
5-9	263	24	9.1	5.6 to 12.6	1.10	0.6 to 2.00	.754			
10-15	449	33	7.3	4.9 to 9.8	0.87	0.5 to 1.51	.620			
ime since diagnosis, vears										
5-14	260	17	6.5	3.5 to 9.5	1.00					
15-19	263	26	9.9	6.3 to 13.5	1.57	0.83 to 2.96	166			
20-24	258	18	7.0	3.9 to 10.1	1.07	0.54 to 2.13	843			
> 25	206	19	9.2	5.3 to 13.2	1.07	0.73 to 2.87	283			
	200	10	0.2	0.0 10 10.2	1.10	0.70 10 2.07	.200			
	364	34	03	6 / to 12 3	1 00					
Leukenna	212	15	7 1	3.6 to 10.5	0.74	0 39 to 1 39	3/10			
	115	10	10.4	4.9 to 16.0	1 12	0.59 to 1.59	.343			
Other tumor	204	12	10.4 6 F	4.0 10 10.0	0.67	0.30 10 2.20	.729			
	294	19	0.5	3.7 10 9.3	0.67	0.37 to 1.20	.180			
Current	400	20	7.0	F 0 ++ 0 7	1 00					
Surgery	490	30	7.3	5.0 to 9.7	1.00	0.04 0.40	000			
Chemotherapy	402	39	9.7	6.8 to 12.6	1.35	0.84 to 2.18	.209			
RadiotherapyT	87	5	5.7	0.9 to 10.6	0.77	0.29 to 2.02	.593			
IMI	0.40									
INO	948	/5	/.9	6.2 to 9.6	1.00					
Yes	39	5	12.8	2.3 to 23.3	1.71	0.65 to 4.51	.276			
lelapse										
Yes	869	65	7.5	5.7 to 9.2	1.00					
No	118	15	12.7	6.7 to 18.7	1.8	0.99 to 3.27	.054			
ate effects										
No late effects	595	28	4.7	3.0 to 6.4	1.00			1.00		
Somatic problems only	273	28	10.3	6.7 to 13.9	2.31	1.34 to 3.99	.003	2.12	1.22 to 3.71	.00
Psychological problems‡	107	20	18.7	11.3 to 26.1	4.66	2.51 to 8.62	< .001	4.12	2.19 to 7.78	< .00

Table A2. Characteristics of	Survivors With High Potential Ex	Risk of F planator	sycholog / Factors	ical Distress (cas by Univariable a	senesss, nd Multiv	$T \ge 63$ ) in Obsess ariable Logistic Re	sive-Compul gression	sive Dom	nain and Associatio	on With
			Cas	ies	L	Inivariable Regres	sion	Μ	lultivariable Regres	sion
Factor	No. of Survivors	No.	%	95% CI	OR	95% CI	Р	OR	95% CI	Р
Sex										
Male	535	43	8.0	5.7 to 10.3	1.00			1.00		
Female	452	61	13.5	10.3 to 16.6	1.79	1.18 to 2.70	.006	1.58	1.02 to 2.46	.042
Current age, years										
20-24	373	32	8.6	5.7 to 11.4	1.00					
25-29	292	31	10.6	7.1 to 14.1	1.27	0.75 to 2.13	.374			
≥ 30	318	41	12.9	9.2 to 16.6	1.58	0.97 to 2.57	.068			
Siblings										
Yes	888	90	10.1	8.2 to 12.1	1.00					
No	99	14	14.1	7.3 to 21.0	1.46	0.80 to 2.68	.221			
Immigration status										
Native Swiss	927	95	10.2	8.3 to 12.2	1.00					
Immigrant	54	8	14.8	5.3 to 24.3	1.52	0.70 to 3.32	.291			
Education										
Other degree	912	93	10.2	8.2 to 12.2	1.00					
University degree	75	11	14.7	6.7 to 22.7	1.51	0.77 to 2.97	.229			
Employment										
Employed	901	91	10.1	8.1 to 12.1	1.00			1.00		
Unemployed	65	13	20.0	10.3 to 29.7	2.23	1.17 to 4.24	.015	1.69	0.83 to 3.47	.150
Income, CHF										
< 3,001	389	46	11.8	8.6 to 15.0	1.00					
3,001-4,500	279	28	10.0	6.5 to 13.6	0.83	0.51 to 1.37	.468			
> 4,500	273	23	8.4	5.1 to 11.7	0.69	0.41 to 1.16	.161			
Age at diagnosis, years										
0-4	275	21	7.6	4.5 to 10.8	1.00			1.00		
5-9	263	25	9.5	6.0 to 13.1	1.27	0.69 to 2.33	.439	1.19	0.62 to 2.28	.604
10-15	449	58	12.9	9.8 to 16.0	1.79	1.06 to 3.03	.029	1.47	0.78 to 2.75	.230
Time since diagnosis, years										
5-14	260	31	11.9	8.0 to 15.9	1.00			1.00		
15-19	263	33	12.5	8.5 to 16.6	1.06	0.63 to 1.79	.828	1.34	0.74 to 2.43	.331
20-24	258	16	6.2	3.3 to 9.1	0.49	0.26 to 0.92	.026	0.61	0.29 to 1.27	.184
≥ 25	206	24	11.7	7.3 to 16.0	0.97	0.55 to 1.72	.928	1.31	0.66 to 2.59	.440
Diagnosis										
Leukemia	364	38	10.4	7.3 to 13.6	1.00					
Lymphoma	212	23	10.8	6.7 to 15.0	1.04	0.60 to 1.81	.878			
CNS tumor	115	17	14.8	8.3 to 21.3	1.49	0.80 to 2.75	.205			
Other tumor	294	26	8.8	5.6 to 12.1	0.83	0.49 to 1.41	.493			
Treatment										
Surgery	490	41	8.4	5.9 to 10.8	1.00			1.00		
Chemotherapy*	402	53	13.2	9.9 to 16.5	1.66	1.08 to 2.56	.021	1.22	0.75 to 1.99	.430
Radiotherapy <sup>+</sup>	87	10	11.5	4.8 to 18.2	1.42	0.68 to 2.96	.346	1.17	0.54 to 2.55	.696
BMT										
No	948	100	10.5	8.6 to 12.5	1.00					
Yes	39	4	10.3	0.7 to 19.8	0.97	0.34 to 2.78	.954			
Relapse										
Yes	869	94	10.8	8.8 to 12.9	1.00					
No	118	10	8.5	3.4 to 13.5	0.76	0.39 to 1.51	.438			
Late effects										
No late effects	595	37	6.2	4.3 to 8.2	1.00			1.00		
Somatic problems only	273	32	11.7	7.9 to 15.5	2.00	1.22 to 3.29	.006	1.65	0.98 to 2.80	.060
Psychological problems‡	107	33	30.8	22.1 to 39.6	6.73	3.97 to 11.41	< .001	5.78	3.33 to 10.04	< .001

Abbreviations: OR, odds ratio; CHF, Swiss franc; BMT, bone marrow transplantation.

\*Survivor had chemotherapy and may have had surgery but no radiotherapy. †Survivor may have had chemotherapy and surgery. ‡May include somatic problems.

12 © 2010 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY

			Cas	es	ι	Jnivariable Regres	sion	M	ultivariable Regre	ssion
Factor	No. of Survivors	No.	%	95% CI	OR	95% CI	P	OR	95% CI	P
Sex										
Male	535	55	10.3	7.7 to 12.9	1.00			1.00		
Female	452	108	23.9	20.0 to 27.8	2.74	1.93 to 3.90	< .001	2.46	1.66 to 3.64	< .001
Current age, years										
20-24	373	64	17.2	13.3 to 21.0	1.00					
25-29	292	50	17.1	12.8 to 21.4	1.00	0.66 to 1.50	.991			
$\geq 30$	318	49	15.4	11.4 to 19.4	0.88	0.59 to 1.32	.536			
Siblings										
Yes	888	142	16.0	13.6 to 18.4	1.00					
No	99	21	21.2	13.2 to 29.3	1.41	0.85 to 2.37	.186			
Immigration status										
Native Swiss	927	150	16.2	13.8 to 18.6	1.00					
Immigrant	54	13	24.1	12.7 to 35.5	1.64	0.86 to 3.14	.133			
Education										
Other degree	912	153	16.8	14.4 to 19.2	1.00					
University degree	75	10	13.3	5.6 to 21.0	0.76	0.38 to 1.52	.441			
Employment										
Employed	901	143	15.9	13.5 to 18.3	1.00			1.00		
Unemployed	65	18	27.7	16.8 to 38.6	2.03	1.15 to 3.60	.015	1.34	0.68 to 2.62	.401
Income, CHF										
< 3,001	389	77	19.8	15.8 to 23.8	1.00			1.00		
3,001-4,500	279	46	16.5	12.1 to 20.8	0.80	0.53 to 1.20	.277	1.06	0.69 to 1.65	.779
> 4,500	273	30	11.0	7.3 to 14.7	0.50	0.32 to 0.79	.003	0.79	0.48 to 1.30	.357
Age at diagnosis, years										
0-4	275	41	14.9	10.7 to 19.1	1.00					
5-9	263	41	15.6	11.2 to 20.0	1.05	0.66 to 1.69	.826			
10-15	449	81	18.0	14.5 to 21.6	1.26	0.83 to 1.89	.275			
Time since diagnosis, years										
5-14	260	48	18.5	13.7 to 23.2	1.00					
15-19	263	52	19.8	15.0 to 24.6	1.09	0.70 to 1.68	.703			
20-24	258	36	14.0	9.7 to 18.2	0.72	0.45 to 1.15	.165			
≥ 25	206	27	13.1	8.5 to 17.7	0.67	0.40 to 1.11	.120			
Diagnosis										
Leukemia	364	67	18.4	14.4 to 22.4	1.00					
Lymphoma	212	27	12.7	8.2 to 17.2	0.65	0.40 to 1.05	.077			
CNS tumor	115	26	22.6	15.0 to 30.3	1.29	0.78 to 2.16	.322			
Other tumor	294	43	14.6	10.6 to 18.7	0.76	0.50 to 1.15	.197			
Treatment										
Surgery	490	76	15.5	12.3 to 18.7	1.00					
Chemotherapy*	402	72	17.9	14.2 to 21.7	1.19	0.83 to 1.69	.338			
Radiotherapy†	87	14	16.1	8.4 to 23.8	1.04	0.56 to 1.95	.890			
BMT										
No	948	155	16.4	14.0 to 18.7	1.00					
Yes	39	8	20.5	7.8 to 33.2	1.32	0.60 to 2.93	.494			
Relapse										
Yes	869	148	17.0	14.5 to 19.5	1.00					
No	118	15	12.7	6.7 to 18.7	0.71	0.40 to 1.25	.238			
Late effects										
No late effects	595	61	10.3	7.8 to 12.7	1.00			1.00		
Somatic problems only	273	54	19.8	15.1 to 24.5	2.16	1.45 to 3.22	< .001	1.85	1.21 to 2.81	.004
Psychological problems‡	107	47	43.9	34.5 to 53.3	6.86	4.31 to 10.91	< .001	5.93	3.62 to 9.72	< .001

Table A4. Characteristics of	f Survivors With High Explana	Risk of atory Fac	Psycholo tors by U	gical Distress (ca nivariable and M	isenesss, Iultivariab	$T \ge 63$ ) in Depres le Logistic Regres	ssion Doma sion	in and As	ssociation With Po	otential
			Cas	es	L	Inivariable Regres	sion	Μ	lultivariable Regre	ssion
Factor	No. of Survivors	No.	%	95% CI	OR	95% CI	Р	OR	95% CI	Р
Sex										
Male	535	57	10.7	8.0 to 13.3	1.00			1.00		
Female	452	75	16.6	13.2 to 20.0	1.67	1.15 to 2.42	.007	1.32	0.86 to 2.03	.200
Current age, years										
20-24	373	46	12.3	9.0 to 15.7	1.00					
25-29	292	41	14.0	10.1 to 18.0	1.16	0.74 to 1.82	.517			
≥ 30	318	45	14.2	10.3 to 18.0	1.17	0.75 to 1.82	.481			
Siblings	010	.0		1010 10 1010		0170 10 1102				
Ves	888	11/	12.8	10.6 to 15.0	1 00					
Ne	000	10	10.0	10.0 to 15.0	1.00	0.97 +0.2 61	1./ 1			
	99	10	10.2	10.0 10 25.8	1.01	0.07 10 2.01	.141			
Immigration status	007	100		40.0.454						
Native Swiss	927	120	12.9	10.8 to 15.1	1.00	0.00.075				
Immigrant	54	12	22.2	11.1 to 33.3	1.92	0.98 to 3.75	.056			
Education										
Other degree	912	120	13.2	11.0 to 15.4	1.00					
University degree	75	12	16.0	7.7 to 24.3	1.26	0.66 to 2.40	.488			
Employment										
Employed	901	113	12.5	10.4 to 14.7	1.00			1.00		
Unemployed	65	17	26.2	15.5 to 36.8	2.47	1.37 to 4.44	.003	1.85	0.91 to 3.76	.091
Income, CHF										
< 3.001	389	56	14.4	10.9 to 17.9	1.00			1.00		
3 001-4 500	279	40	14.3	10 2 to 18 4	1.00	0.64 to 1.54	983	1.34	0.82 to 2.17	242
> 4 500	273	23	8.4	5.1 to 11.7	0.55	0.33 to 0.91	021	0.80	0.46 to 1.41	444
	270	20	0.1	0.1 to 11.7	0.00	0.00 10 0.01	.021	0.00	0.10 10 1.11	
	275	20	10.0	7.2 to 14.6	1.00					
0-4 F 0	275	30	10.9	7.2 to 14.0	1.00	0 7E to 0 11	204			
5-9	203	35	13.3	9.2 10 17.4	1.25	0.75 to 2.11	.394			
10-15	449	67	14.9	11.6 to 18.2	1.43	0.90 to 2.27	.125			
lime since diagnosis, years										
5-14	260	39	15.0	10.7 to 19.3	1.00					
15-19	263	38	14.4	10.2 to 18.7	0.96	0.59 to 1.55	.859			
20-24	258	32	12.4	8.4 to 16.4	0.80	0.49 to 1.33	.391			
≥ 25	206	23	11.2	6.9 to 15.5	0.71	0.41 to 1.24	.228			
Diagnosis										
Leukemia	364	44	12.1	8.7 to 15.4	1.00					
Lymphoma	212	24	11.3	7.1 to 15.6	0.93	0.55 to 1.58	.783			
CNS tumor	115	19	16.5	9.7 to 23.3	1.44	0.80 to 2.58	.222			
Other tumor	294	45	15.3	11.2 to 19.4	1.31	0.84 to 2.06	.231			
Treatment										
Surgery	/90	56	11 /	8.6 to 1/1.2	1 00			1 00		
Chomothorapy*	400	58	1/1.4	11 0 to 17 9	1.00	0.88 to 1.94	183	0.01	0 58 to 1 11	701
Padiatharapy <sup>+</sup>	402	17	14.4	11.0 to 17.9	1.01	1 02 to 2 42	.100	1.05	0.06 to 2.57	.701
паціотпетарут	07	17	19.0	11.2 to 27.9	1.00	1.03 10 3.42	.030	1.00	0.90 10 3.57	.007
BIVIT	0.40	100	10.0	10.0 +- 15.1	1 00					
INO	948	123	13.0	10.8 to 15.1	1.00		075			
Yes	39	9	23.1	9.9 to 36.3	2.01	0.93 to 4.34	.075			
Relapse										
Yes	869	117	13.5	11.2 to 15.7	1.00					
No	118	15	12.7	6.7 to 18.7	0.94	0.53 to 1.66	.822			
Late effects										
No late effects	595	43	7.2	5.1 to 9.3	1.00			1.00		
Somatic problems only	273	47	17.2	12.7 to 21.7	2.67	1.72 to 4.15	< .001	2.50	1.53 to 4.08	< .001
Psychological problems‡	107	40	37.4	28.2 to 46.6	7.66	4.65 to 12.63	< .001	7.29	4.23 to 12.59	< .001

Abbreviations: OR, odds ratio; CHF, Swiss franc; BMT, bone marrow transplantation.

\*Survivor had chemotherapy and may have had surgery but no radiotherapy. †Survivor may have had chemotherapy and surgery. ‡May include somatic problems.

14 © 2010 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY

			Cas	es	U	nivariable Regres	sion	M	ultivariable Regre	ssion
Factor	No. of Survivors	No.	%	95% CI	OR	95% CI	P	OR	95% CI	P
Sex										
Male	535	59	11.0	8.4 to 13.7	1.00					
Female	452	67	14.8	11.5 to 18.1	1.40	0.97 to 2.04	.076			
Current age, years										
20-24	373	41	11.0	7.8 to 14.2	1.00					
25-29	292	39	13.4	9.5 to 17.3	1.25	0.78 to 1.99	.353			
≥ 30	318	46	14.5	10.6 to 18.3	1.37	0.87 to 2.15	.171			
Siblings										
Yes	888	105	11.8	9.7 to 13.9	1.00			1.00		
No	99	21	21.2	13.2 to 29.3	2.01	1.19 to 3.39	.009	2.13	1.24 to 3.67	.006
Immigration status										
Native Swiss	927	113	12.2	10.1 to 14.3	1 00			1 00		
Immigrant	54	12	22.2	11 1 to 33 3	2.06	1 05 to 4 03	035	2 24	1 12 to 4 49	023
Education		12	22.2	11.1 10 00.0	2.00	1.00 to 4.00	.000	2.27	1.12 to 4.40	.020
Other degree	012	110	10.0	10 2 to 14 4	1.00					
	912	112	12.3	10.2 to 14.4	1.00	0.00 to 2.02	111			
University degree	/5	14	18.7	9.8 10 27.5	1.04	0.89 10 3.03	.114			
Employment										
Employed	901	112	12.4	10.3 to 14.6	1.00					
Unemployed	65	12	18.5	9.0 to 27.9	1.60	0.83 to 3.08	.164			
Income, CHF										
< 3,001	389	54	13.9	10.4 to 17.3	1.00					
3,001-4,500	279	30	10.8	7.1 to 14.4	0.75	0.46 to 1.20	.230			
> 4,500	273	34	12.5	8.5 to 16.4	0.88	0.56 to 1.40	.594			
Age at diagnosis, years										
0-4	275	29	10.5	6.9 to 14.2	1.00					
5-9	263	34	12.9	8.9 to 17.0	1.26	0.74 to 2.13	.391			
10-15	449	63	14.0	10.8 to 17.2	1.38	0.87 to 2.21	.173			
Time since diagnosis, years										
5-14	260	34	13.1	9.0 to 17.2	1 00					
15-19	263	37	1/1 1	9.9 to 18.3	1.09	0.66 to 1.80	7/1			
20.24	200	20	14.1	7.7 to 15.5	0.07	0.50 to 1.00	616			
> 25	206	25	10.1	7.7 to 15.5	0.07	0.52 to 1.40	.010			
≥ 20 Diamania	200	20	12.1	7.7 10 10.0	0.92	0.55 10 1.59	.702			
Diagnosis				0.0. 45 7						
Leukemia	364	45	12.4	9.0 to 15.7	1.00					
Lymphoma	212	24	11.3	7.1 to 15.6	0.90	0.53 to 1.53	.710			
CNS tumor	115	13	11.3	5.5 to 17.1	0.90	0.47 to 1.74	.762			
Other tumor	294	44	15.0	10.9 to 19.0	1.25	0.80 to 1.95	.332			
Treatment										
Surgery	490	48	9.8	7.2 to 12.4	1.00			1.00		
Chemotherapy*	402	64	15.9	12.3 to 19.5	1.74	1.17 to 2.60	.006	1.44	0.94 to 2.21	.094
Radiotherapy†	87	14	16.1	8.4 to 23.8	1.77	0.93 to 3.37	.084	1.64	0.85 to 3.17	.144
BMT										
No	948	120	12.7	10.5 to 14.8	1.00					
Yes	39	6	15.4	4.1 to 26.7	1.25	0.51 to 3.06	.618			
Relapse		-			-					
Yes	869	112	12.9	10.7 to 15.1	1 00					
No	118	1/	11 9	6 0 to 17 7	0.91	0.50 to 1.64	755			
Late offects	110	14	11.5	0.01017.7	0.91	0.00101.04	.700			
	FOF	<b>E</b> 4	0.1	6 9 to 11 4	1 00			1 00		
	020	54	9.1	0.01011.4	1.00	1 15 + 0 70	040	1.00	1.04+ 0.50	005
Somatic problems only	2/3	41	15.0	10.8 to 19.3	1.//	1.15 to 2.73	.010	1.64	1.04 to 2.59	.035
Psychological problems‡	107	29	27.1	18.7 to 35.5	3.72	2.24 to 6.20	< .001	3.88	2.30 to 6.57	< .001

Table A6. Characteristics of	Survivors With High Explana	Risk of I tory Fact	<sup>D</sup> sycholog tors by Ur	ical Distress (cas nivariable and Mu	enesss, T Iltivariable	$\ge$ 63) in Aggres	sion Domai sion	n and Ass	sociation With Po	tential
			Cas	es	U	nivariable Regres	sion	Mu	ultivariable Regres	ssion
Factor	No. of Survivors	No.	%	95% CI	OR	95% CI	Р	OR	95% CI	Р
Sex										
Male	535	82	15.3	12.3 to 18.4	1.00					
Female	452	85	18.8	15.2 to 22.4	1.28	0.92 to 1.79	.147			
Current age, years										
20-24	373	65	17.4	13.6 to 21.3	1.00					
25-29	292	49	16.8	12.5 to 21.1	0.96	0.64 to 1.44	.827			
≥ 30	318	53	16.7	12.6 to 20.8	0.95	0.64 to 1.41	.791			
Siblings	000			40.0.40.0						
Yes	888	144	16.2	13.8 to 18.6	1.00	0.05 / 0.50	070			
INO	99	23	23.2	14.9 to 31.6	1.56	0.95 to 2.58	.079			
Immigration status	007	4.40	10.1	407.404	4.00			1.00		
Native Swiss	927	149	16.1	13.7 to 18.4	1.00	1 44+- 4 70	001	1.00	1 54 +- 5 04	001
Immigrant	54	18	33.3	20.8 to 45.9	2.61	1.44 to 4.72	.001	2.84	1.54 to 5.24	.001
Other degree	010	154	10.0	14 E to 10 0	1.00					
	912	104	10.9	14.5 10 19.3	1.00	0 55 to 1 02	021			
Employment	75	15	17.5	0.0 10 20.9	1.03	0.55 to 1.92	.921			
Employed	001	152	17.0	14 5 to 19 4	1.00					
Linemployed	65	133	20.0	14.5 to 19.4	1.00	0.65 to 2.30	53/			
	00	15	20.0	10.3 to 23.7	1.22	0.03 10 2.30	.004			
< 3 001	389	73	18.8	1/1 9 to 22 6	1.00					
3 001-4 500	279	/6	16.5	12 1 to 20.8	0.85	0 57 to 1 28	118			
> 4 500	273	37	13.6	9.5 to 17.6	0.68	0.07 to 1.20	077			
Age at diagnosis years	270	07	10.0	0.0 10 17.0	0.00	0.11101.01	.077			
0-4	275	45	16.4	12.0 to 20.7	1 00					
5-9	263	41	15.6	11.2 to 20.0	0.94	0.59 to 1.50	.806			
10-15	449	81	18.0	14.5 to 21.6	1.13	0.75 to 1.68	.564			
Time since diagnosis, years										
5-14	260	48	18.5	13.7 to 23.2	1.00					
15-19	263	49	18.6	13.9 to 23.3	1.01	0.65 to 1.57	.960			
20-24	258	45	17.4	12.8 to 22.1	0.93	0.60 to 1.46	.762			
≥ 25	206	25	12.1	7.7 to 16.6	0.61	0.36 to 1.03	.064			
Diagnosis										
Leukemia	364	65	17.9	13.9 to 21.8	1.00					
Lymphoma	212	28	13.2	8.6 to 17.8	0.70	0.43 to 1.13	.145			
CNS tumor	115	20	17.4	10.5 to 24.3	0.97	0.56 to 1.68	.909			
Other tumor	294	54	18.4	13.9 to 22.8	1.04	0.69 to 1.54	.866			
Treatment										
Surgery	490	80	16.3	13.1 to 19.6	1.00					
Chemotherapy*	402	70	17.4	13.7 to 21.1	1.08	0.76 to 1.54	.666			
Radiotherapy†	87	17	19.5	11.2 to 27.9	1.24	0.70 to 2.23	.461			
BMT										
No	948	160	16.9	14.5 to 19.3	1.00					
Yes	39	7	17.9	5.9 to 30.0	1.08	0.47 to 2.48	.861			
Relapse										
Yes	869	149	17.1	14.6 to 19.7	1.00					
No	118	18	15.3	8.8 to 21.7	0.87	0.51 to 1.48	.607			
Late effects	505		46.4	05	4.00			4.00		
No late effects	595	72	12.1	9.5 to 14.7	1.00	4.40 - 0.55	~~~	1.00	4 4 9 4 9 5 5 5	~~~
Somatic problems only	2/3	52	19.0	14.4 to 23.7	1.71	1.16 to 2.52	.007	1.72	1.16 to 2.55	.007
Psychological problems‡	107	42	39.3	30.0 to 48.5	4.69	2.96 to 7.43	< .001	4.90	3.08 to 7.79	< .001

Abbreviations: OR, odds ratio; CHF, Swiss franc; BMT, bone marrow transplantation.

\*Survivor had chemotherapy and may have had surgery but no radiotherapy. †Survivor may have had chemotherapy and surgery. ‡May include somatic problems.

16 © 2010 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY

			Cas	ses	L	Inivariable Regres	sion	M	ultivariable Regre	ssion
Factor	No. of Survivors	No.	%	95% CI	OR	95% CI	Р	OR	95% CI	Р
Sex										
Male	535	41	7.7	5.4 to 9.9	1.00			1.00		
Female	452	60	13.3	10.1 to 16.4	1.84	1.21 to 2.80	.004	1.67	1.04 to 2.67	.034
Current age, years										
20-24	373	36	9.7	6.7 to 12.6	1.00					
25-29	292	33	11.3	7.7 to 14.9	1.19	0.72 to 1.97	.489			
≥ 30	318	32	10.1	6.8 to 13.4	1.05	0.63 to 1.73	.856			
Siblings										
Yes	888	84	9.5	7.5 to 11.4	1.00			1.00		
No	99	17	17.2	9.7 to 24.6	1.98	1.12 to 3.50	.018	2.35	1.26 to 4.37	.007
mmigration status										
Native Swiss	927	95	10.2	8.3 to 12.2	1.00					
Immigrant	54	6	11.1	2.7 to 19.5	1.09	0.46 to 2.63	.839			
Education										
Other degree	912	91	10.0	8.0 to 11.9	1.00					
University degree	75	10	13.3	5.6 to 21.0	1.39	0.69 to 2.80	.359			
Employment										
Employed	901	85	9.4	7.5 to 11.3	1.00			1.00		
Unemployed	65	15	23.1	12.8 to 33.3	2.88	1.55 to 5.35	.001	1.89	0.93 to 3.86	.080
Income, CHF										
< 3.001	389	52	13.4	10.0 to 16.7	1.00			1.00		
3.001-4.500	279	21	7.5	4.4 to 10.6	0.53	0.31 to 0.90	.018	0.65	0.37 to 1.16	.145
> 4 500	273	22	81	4.8 to 11.3	0.57	0.34 to 0.96	035	0.85	0.48 to 1.51	580
Age at diagnosis years	270		0.1	110 10 1110	0.07	0.01 10 0.00	.000	0.00	0110 10 1101	.000
0_1	275	26	95	6.0 to 12.9	1 00					
5-9	263	20	8.4	5.0 to 11.7	0.87	0.48 to 1.58	658			
10-15	200	53	11.8	8.8 to 1/1.8	1.28	0.78 to 2.10	326			
Timo sinco diagnosis voars	445	55	11.0	0.0 10 14.0	1.20	0.70 to 2.10	.520			
5-14	260	33	127	8.6 to 16.7	1 00					
15 10	200	22	12.7	6.0 to 10.7	0.02	0.49 to 1.40	467			
15-19	203	28	10.6	6.9 l0 14.4	0.82	0.48 to 1.40	.407			
20-24	258	22	8.5	5.1 to 11.9	0.64	0.36 to 1.13	.120			
≥ 25 D:	206	18	8.7	4.9 to 12.6	0.66	0.36 to 1.21	.1//			
Diagnosis	004			70.440						
Leukemia	364	40	11.0	7.8 to 14.2	1.00		0.54			
Lymphoma	212	17	8.0	4.4 to 11.7	0.71	0.39 to 1.28	.251			
CNS tumor	115	17	14.8	8.3 to 21.3	1.41	0.76 to 2.59	.275			
Other tumor	294	27	9.2	5.9 to 12.5	0.82	0.49 to 1.37	.447			
Treatment										
Surgery	490	45	9.2	6.6 to 11.7	1.00					
Chemotherapy*	402	48	11.9	8.8 to 15.1	1.34	0.87 to 2.06	.181			
Radiotherapy†	87	8	9.2	3.1 to 15.3	1.00	0.45 to 2.20	.997			
BMT										
No	948	97	10.2	8.3 to 12.2	1.00					
Yes	39	4	10.3	0.7 to 19.8	1.00	0.35 to 2.88	.996			
Relapse										
Yes	869	92	10.6	8.5 to 12.6	1.00					
No	118	9	7.6	2.8 to 12.4	0.70	0.34 to 1.42	.322			
Late effects										
No late effects	595	35	5.9	4.0 to 7.8	1.00			1.00		
Somatic problems only	273	34	12.5	8.5 to 16.4	2.28	1.39 to 3.74	.001	1.86	1.11 to 3.11	.019
,,	107	20	00.0	10 E to 20 E	0.00	0.00 +- 10.70	< 001	E 20	2 02 40 0 24	- 001

Table A8. Characteristics	of Survivors With Hig Explana	h Risk o atory Fac	f Psychol tors by L	ogical Distress (o Inivariable and N	caseness Iultivariab	s, T $\geq$ 63) in Parar le Logistic Regres	noid Ideation sion	n and Ass	sociation With Pot	ential
			Cas	es	L	Jnivariable Regres	sion	Μ	lultivariable Regres	sion
Factor	No. of Survivors	No.	%	95% CI	OR	95% CI	Р	OR	95% CI	Р
Sex										
Male	535	51	9.5	7.0 to 12.0	1.00			1.00		
Female	452	64	14.2	10.9 to 17.4	1.57	1.06 to 2.32	.025	1.22	0.80 to 1.85	.363
Current age, years										
20-24	373	42	11.3	8.1 to 14.5	1.00					
25-29	292	36	12.3	8.6 to 16.1	1.11	0.69 to 1.78	.671			
≥ 30	318	37	11.6	8.1 to 15.2	1.04	0.65 to 1.66	.877			
Siblings										
Yes	888	96	10.8	8.8 to 12.9	1.00			1.00		
No	99	19	19.2	11.4 to 26.9	1.96	1.14 to 3.37	.015	2.24	1.25 to 4.02	.007
Immigration status										
Native Swiss	927	103	11.1	9.1 to 13.1	1.00			1.00		
Immigrant	54	12	22.2	11.1 to 33.3	2.29	1.17 to 4.48	.016	2.46	1.17 to 5.18	.018
Education										
Other degree	912	109	12.0	9.8 to 14.1	1.00					
University degree	75	6	8.0	1.9 to 14.1	0.64	0.27 to 1.51	.309			
Employment										
Employed	901	103	11.4	9.4 to 13.5	1.00					
Unemployed	65	12	18.5	9.0 to 27.9	1.75	0.91 to 3.39	.095			
Income, CHF										
< 3 001	389	48	12.3	9 1 to 15 6	1 00					
3 001-4 500	279	36	12.9	9.0 to 16.8	1.05	0.66 to 1.67	828			
> 4 500	273	23	8.4	5.1 to 11.7	0.65	0.39 to 1.10	111			
Age at diagnosis years	270	20	0.1	0.11011.7	0.00	0.00 10 1.10				
	275	27	9.8	63 to 133	1 00					
5-9	273	2/	12.9	8.9 to 17.0	1.00	0.80 to 2.33	257			
10-15	200	54	12.0	9.0 to 15.0	1.00	0.00 to 2.00	361			
Time since diagnosis years	440	54	12.0	5.0 10 15.0	1.20	0.77 to 2.05	.501			
5-14	260	33	127	8.6 to 16.7	1 00					
15 10	200	25	12.7	0.0 to 10.7	1.00	0.62 to 1.76	024			
15-19	203	30	13.3	9.2 to 17.4	1.00	0.03 to 1.70	.034			
20-24	258	23	8.9 11 7	5.4 LO 12.4	0.07	0.38 to 1.18	.108			
	200	24	11.7	7.3 10 10.0	0.91	0.52 10 1.59	./00			
Diagnosis	004	20	107	7 5 += 10 0	1 00			1 00		
Leukemia	364	39	10.7	7.5 to 13.9	1.00	0.00 / 0.01	000	1.00	0.40 - 0.77	000
Lymphoma	212	11	5.2	2.2 to 8.2	0.46	0.23 to 0.91	.026	0.37	0.18 to 0.77	.008
CNS tumor	115	19	16.5	9.7 to 23.3	1.65	0.91 to 2.99	.099	0.77	0.36 to 1.65	.499
Other tumor	294	46	15.6	11.5 to 19.8	1.55	0.98 to 2.44	.062	1.29	0.77 to 2.14	.331
Ireatment										
Surgery	490	45	9.2	6.6 to 11.7	1.00			1.00		
Chemotherapy*	402	54	13.4	10.1 to 16.8	1.53	1.01 to 2.33	.046	1.38	0.86 to 2.23	.187
Radiotherapy†	87	15	17.2	9.3 to 25.2	2.06	1.09 to 3.89	.026	1.94	0.89 to 4.25	.097
BMT										
No	948	107	11.3	9.3 to 13.3	1.00					
Yes	39	8	20.5	7.8 to 33.2	2.03	0.91 to 4.53	.084			
Relapse										
Yes	869	100	11.5	9.4 to 13.6	1.00					
No	118	15	12.7	6.7 to 18.7	1.12	0.63 to 2.00	.702			
Late effects										
No late effects	595	39	6.6	4.6 to 8.5	1.00			1.00		
Somatic problems only	273	41	15.0	10.8 to 19.3	2.52	1.58 to 4.01	< .001	2.30	1.39 to 3.79	.001
Psychological problems‡	107	33	30.8	22.1 to 39.6	6.36	3.77 to 10.73	< .001	6.73	3.83 to 11.83	< .001

Abbreviations: OR, odds ratio; CHF, Swiss franc; BMT, bone marrow transplantation.

\*Survivor had chemotherapy and may have had surgery but no radiotherapy. †Survivor may have had chemotherapy and surgery. ‡May include somatic problems.

18 © 2010 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY

Factor	No. of Survivors	Cases			Univariable Regression			Multivariable Regression		
		No.	%	95% CI	OR	95% Cl	P	OR	95% Cl	P
Sex										
Male	535	70	13.1	10.2 to 15.9	1.00			1.00		
Female	452	84	18.6	15.0 to 22.2	1.52	1.07 to 2.14	.018	1.27	0.88 to 1.84	.207
Current age, years										
20-24	373	48	12.9	9.5 to 16.3	1.00			1.00		
25-29	292	43	14.7	10.7 to 18.8	1.17	0.75 to 1.82	.489	1.29	0.81 to 2.05	.288
≥ 30	318	63	19.8	15.4 to 24.2	1.67	1.11 to 2.52	.014	1.70	1.08 to 2.66	.021
Siblings	000	101	45.4	4074 474	1.00					
Yes	888	134	15.1	12.7 to 17.4	1.00	0.04 += 0.44	100			
NO	99	20	20.2	12.3 to 28.1	1.42	0.84 to 2.41	.186			
Immigration status	007	1 4 0	1 - 1	10.1 +- 17.0	1 00					
Native Swiss	927	143	15.4	13.1 to 17.8	1.00	0.71 to 0.70	224			
Immigrant	54	11	20.4	9.6 10 31.1	1.40	0.71 to 2.78	.334			
Other degree	010	145	15.0	12 E to 19 2	1.00					
	912	140	12.9	13.5 to 10.3	0.72	0.25 to 1.49	272			
Employment	75	9	12.0	4.0 10 19.4	0.72	0.35 10 1.46	.575			
Employed	001	122	1/0	12 / to 17 1	1.00			1 00		
Linemployed	65	20	30.8	12.4 to 17.1	2.57	1 47 to 4 48	001	1.00	1.06 to 3.60	033
	00	20	50.0	10.0 10 42.0	2.07	1.47 10 4.40	.001	1.55	1.00 to 3.00	.002
	389	65	16.7	13.0 to 20.4	1 00					
3 001-4 500	279	41	14.7	10.5 to 18.8	0.86	0.56 to 1.31	483			
> 4 500	273	38	13.9	9.8 to 18.0	0.81	0.52 to 1.24	. 100			
Age at diagnosis years	270	00	10.0	0.0 10 10.0	0.01	0.02 10 1.2 1	.000			
0-4	275	35	12 7	8 8 to 16 7	1 00					
5-9	263	43	16.3	11.9 to 20.8	1.34	0.83 to 2.17	.234			
10-15	449	76	16.9	13.5 to 20.4	1.40	0.91 to 2.15	.129			
Time since diagnosis, years										
5-14	260	35	13.5	9.3 to 17.6	1.00					
15-19	263	46	17.5	12.9 to 22.1	1.36	0.85 to 2.20	.204			
20-24	258	36	14.0	9.7 to 18.2	1.04	0.63 to 1.72	.871			
≥ 25	206	37	18.0	12.7 to 23.2	1.41	0.85 to 2.33	.183			
Diagnosis										
Leukemia	364	54	14.8	11.2 to 18.5	1.00					
Lymphoma	212	29	13.7	9.1 to 18.3	0.91	0.56 to 1.48	.703			
CNS tumor	115	21	18.3	11.2 to 25.3	1.28	0.74 to 2.23	.379			
Other tumor	294	50	17.0	12.7 to 21.3	1.18	0.77 to 1.79	.448			
Treatment										
Surgery	490	62	12.7	9.7 to 15.6	1.00			1.00		
Chemotherapy*	402	73	18.2	14.4 to 21.9	1.53	1.06 to 2.21	.023	1.03	0.68 to 1.56	.884
Radiotherapy†	87	18	20.7	12.2 to 29.2	1.80	1.01 to 3.23	.048	1.67	0.91 to 3.06	.099
BMT										
No	948	146	15.4	13.1 to 17.7	1.00					
Yes	39	8	20.5	7.8 to 33.2	1.42	0.64 to 3.15	.391			
Relapse										
Yes	869	134	15.4	13.0 to 17.8	1.00					
No	118	20	16.9	10.2 to 23.7	1.12	0.67 to 1.87	.668			
Late effects										
No late effects	595	61	10.3	7.8 to 12.7	1.00			1.00		
Somatic problems only	273	50	18.3	13.7 to 22.9	1.96	1.31 to 2.94	.001	1.88	1.22 to 2.90	.004
Psychological problems‡	107	40	37.4	28.2 to 46.6	5.23	3.26 to 8.39	< .001	5.07	3.09 to 8.32	< .001